



**HAL**  
open science

## Cancer stem cells in Osteosarcoma

Hannah K Brown, Marta Tellez-Gabriel, Dominique Heymann

► **To cite this version:**

Hannah K Brown, Marta Tellez-Gabriel, Dominique Heymann. Cancer stem cells in Osteosarcoma: Stem cells and osteosarcoma. *Cancer Letters*, 2016, 386, pp.189-195. 10.1016/j.canlet.2016.11.019 . inserm-01466078

**HAL Id: inserm-01466078**

**<https://inserm.hal.science/inserm-01466078>**

Submitted on 13 Feb 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Cancer stem cells in Osteosarcoma

Hannah K. Brown<sup>1, 2</sup>, Marta Tellez-Gabriel<sup>3</sup>, Dominique Heymann<sup>1, 2, 4</sup>

1. Department of Oncology and Metabolism, University of Sheffield, Medical School, Beech Hill Road, S10 2RX, Sheffield, UK
2. European Associated Laboratory, INSERM-University of Sheffield, Sarcoma Research Unit, Medical School, S10 2RX, Sheffield, UK
3. Laboratotoio Hematologia Oncologica y de Transplantes, Institut Investigacions Biomèdiques (IBB) Sant Pau, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
4. INSERM, UMR 957, Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, Equipe Ligue 2012, University of Nantes, Faculty of Medicine, 44035 Nantes, France

**Running title:** Stem cells and osteosarcoma

**Corresponding authors:**

Prof. Dominique Heymann and Dr Hannah Brown

Department of Oncology and Metabolism

Medical School

Beech Hill Road, S10 2RX, Sheffield, UK

Tel.: +44 (0) 112 226 8464

E-mail: [dominique.heyman@sheffield.ac.uk](mailto:dominique.heyman@sheffield.ac.uk) and [Hannah.brown@sheffield.ac.uk](mailto:Hannah.brown@sheffield.ac.uk)

**Abstract:**

Osteosarcoma is the most common primary bone tumour in children and adolescents and advanced osteosarcoma patients with evidence of metastasis share a poor prognosis. Osteosarcoma frequently gains resistance to standard therapies highlighting the need for improved treatment regimens and identification of novel therapeutic targets. Cancer stem cells (CSC) represent a sub-type of tumour cells attributed to critical steps in cancer including tumour propagation, therapy resistance, recurrence and in some cases metastasis. Recent published work demonstrates evidence of cancer stem cell phenotypes in osteosarcoma with links to drug resistance and tumorigenesis. In this review we will discuss the commonly used isolation techniques for cancer stem cells in osteosarcoma as well as the identified biochemical and molecular markers.

Keywords: osteosarcoma, bone cancer, cancer stem cell, tumour heterogeneity

## **Cancer stem cells and tumour heterogeneity: what do we know about osteosarcoma?**

Osteosarcoma predominantly initiates in the metaphysis of the long bones with a high prevalence in children and young adults. The origin of a tumour is potentially a single cell located in the bone marrow, which will eventually give rise to a polyclonal, heterogeneous tumour mass. Analysis of tumour heterogeneity allows us to decipher the steps that were taken from the initiating cell to the development of a heterogeneous tumour mass comprised of an array of distinguishable sub-clones. Indeed, osteosarcoma initiates as a monoclonal disease, which quickly develops into a polyclonal disease and is considered one of the most complex cancers in terms of molecular aberration. Deeper insight into this diversity therefore holds great promise to identify markers associated with the most aggressive tumour cells within a tumour mass. The vast heterogeneity found in osteosarcoma is shown in an exome sequencing study in which multiple pathways (14 driver genes) were identified (1). The authors suggest that no single driver gene can be pinpointed to be the cause of the majority of investigated tumours and that several oncogenic pathways cause genetic instability in osteosarcoma development. Importantly, this high level of heterogeneity adds increased complexity for effective treatment strategies, which is clinically reflected in refractory and recurrent disease.

The increasing knowledge of the cancer genome through in depth analysis using for example deep sequencing has significantly added to the understanding of intra-tumour heterogeneity and an evolutionary pattern of a subset of clones within a tumour has been reported (2). New technologies now allow us to view heterogeneity also on a single cell level. This has clearly increased the tumour complexity over performing analysis on bulk tissue showing even deeper levels of intra-tumour heterogeneity in many cancer types (3-6). Single

cell analysis on CSCs in osteosarcoma has, to our knowledge, currently not been reported but could significantly help to understand the diversity of these cells.

### **Cells-of-origin in osteosarcoma and properties of cancer stem cells**

In osteosarcoma several cell-of-origin models have been proposed including transformation of undifferentiated mesenchymal stem cells (MSCs) as well as more committed osteogenic progenitor cells (7) (Figure 1). Osteosarcoma is a bone forming tumour invading frequently the surrounding soft tissues as revealed by conventional imaging associating X-ray and Magnetic Resonance Imaging (MRI) (Figures 1A-C). Osteosarcoma is a vascularized tumour characterized by typical osteoid matrix formed by cancer cells (Figures 1D,E). Evidence comes predominantly from *in vivo* studies using MSCs and/or osteoprogenitors in which for example mutations in genes such as *P53* and *RB* and/or aberrant Hedgehog and NOTCH signalling were shown to induce osteosarcoma (7-9). The terminology of ‘cancer stem cells’ is still under debate with the association to stem cells remaining controversial. Indeed, cancer stem cells and cancer initiating cells are often used interchangeably although they may indeed exhibit different properties. In a cancer stem cell model, tumours are thought to be hierarchically organised with a subpopulation of self-renewing cells at the basis of tumour progression (10). These cancer stem cells (CSCs) are proposed to be unique subsets of clones within a tumour mass attributed with tumour propagation, resistance to therapy and have in some studies been attributed to initiate metastases. Evidence exists in osteosarcoma that patients may present with distant metastases decades after completion of their first treatment (11) potentially further highlighting the tumorigenic characteristics of CSCs although this currently remains speculative. Similar to the origin of osteosarcoma, the

existing hypotheses for the origin of CSCs in general include the transformation of undifferentiated stem cells or more committed cells to gain aberrant self-renewal properties (12). Remarkably, a stem cell transcription factor (Sox2) has been shown to maintain osteosarcoma CSCs (13) through inhibition of the Hippo pathway (14). The complex self-renewal process of normal stem cells (15) is partly regulated by external signals from the surrounding microenvironment, the stem cell niche. Such a specialised microenvironment has also been proposed for CSCs, influencing CSC function and survival and in some cancers these niches (e.g. vascular, immune, bone) may even overlap with the normal stem cell niche (16). In addition, the bone niche and the bone microenvironment that osteosarcoma cells and the putative CSCs are surrounded by apply continuous pressure thus further influencing genomic instability, dormancy and potential new resistant mechanisms (17).

### **Methods to identify cancer stem cells**

Several methods have been developed to identify and isolate CSCs based on their self-renewal properties and have been discussed in detail elsewhere (10, 18, 19). Functional *in vitro* assays are frequently initially applied to enrich for CSCs. This is often followed by more descriptive assays and *in vivo* verification; however, the order and selection of the tests appears to be interchangeable depending on the study. The functional *in vitro* test of formation of tumour spheres under non-adherent and serum-free conditions often serves as the initial step to enrich for CSC-like cell populations (Figure 1F). The standard method to verify CSC candidates *in vivo* is the serial transplantation of isolated putative CSCs into immunocompromised mice to assess tumorigenic capacity at low cell numbers. Both the *in vivo* and *in vitro* functional assays have the disadvantage that truly quiescent CSCs will

possibly not be identified. The functional methods are frequently used in connection with descriptive assays like the measurement of gene expression levels of stem-like factors and identification based on cell surface markers. In order to assess cell populations for proposed drug resistance properties side population analysis (dye exclusion assay and ALDH (aldehyde dehydrogenase) activity are frequently applied to enrich for CSCs with these characteristics. Importantly, all methods require careful consideration because under none of these experimental conditions a pure CSC population or detection of all CSC sub-populations can be assumed. The methods are more likely to enrich the sample for (specific) CSCs through experimentally-induced selection and in some cases environmental pressure. The use of a number of methods including functional experiments and careful interpretation should therefore be applied to CSC research.

### **Identification of cancer stem cells in osteosarcoma**

In the following section the main identified markers and evidence for the existence of CSCs in osteosarcoma will be discussed. The studies were grouped based on their initial enrichment method and an overview can be found in **table 1**.

#### *Side population (dye exclusion assays)*

One main feature of CSCs is their potential to evade treatment and it is suggested that this is achieved through an increase in ATP-binding cassette (ABC) multidrug efflux transporters such as MDR1/ABCB1 and BRCP1/ABCG2 and ABCB5 expression. This trait has been used for CSC identification by measuring the ability of cells to exclude DNA-binding dyes (Hoechst

33342 or Rhodamine 123) by fluorescence-activated cell sorting (18, 20-22). Cells expressing high ABC transporters exclude the dyes and are visible as a 'side population' during analysis. Murase *et al* (23) studied the side population fraction in seven osteosarcoma cell lines but only one line (NY) was reported to have a side population fraction while side population cells were hardly detected in the rest of the cell lines. They also studied one bone human malignant fibrous histiocytoma cell line (MFH2003) which was shown to have the largest side population fraction and to exhibit increased ABCG5 expression as well as cancer-initiating characteristics detected by increased sphere formation and tumour formation *in vivo* when compared to non-side population cells.

A higher detection rate of side population cells in osteosarcoma was shown in human primary samples (24). Downstream analysis of the side population cells showed upregulated gene expression (ABC transporters, Oct4, Nanog), increased sphere formation and higher multidrug resistance to doxorubicin, methotrexate and cisplatin compared to non-side population cells. When injected into immunocompromised mice, the proposed CSCs showed higher tumorigenic potential although non-side population cells at higher numbers could also form tumours. Similar experiments carried out with U2OS cells did not show a side population fraction.

#### *Aldehyde dehydrogenase (ALDH)*

A second, frequently investigated approach through which CSCs apply their chemoresistance is the expression and activity of the drug-detoxifying enzyme ALDH. A subpopulation of ALDH1<sup>high</sup> MG63 cells was detected by Honoki *et al* (25) who further reported ALDH1<sup>high</sup> cells to have increased expression of stem-like genes (Nanog, Oct3/4, Stat3, Sox2), higher



resistance to doxorubicin and cisplatin and increased self-renewal ability as shown by sphere formation. Importantly, ALDH<sup>high</sup> cells were also detected in human osteosarcoma samples and increased ALDH activity was further correlated to metastatic potential (26). It was also shown that inhibition of ALDH activity using disulfiram resulted in reduced cell proliferation suggesting direct targeting of CSC phenotype cells. A second study reported large ALDH-bright cell population in the OS99-1 osteosarcoma cell line compared to lower percentages in Hu09, Saos-2 and MG63 (27). Interestingly, injection of the OS99-1 cells into mice followed by ALDH activity measurement showed a lower ALDH-bright fraction compared to the parental line cultured *in vitro*. The ALDH-bright cells were further characterised to be more tumorigenic *in vivo* and exhibit higher stem like gene expression (Nanog, Sox-2, OCT3/4) compared to ALDH-low cells.

#### *Cell surface markers*

Cell surface markers are arguably the most attractive and sought after identification method of CSCs. A specific cell surface marker exclusively to CSCs and not normal cells, including stem cells, would drastically simplify the isolation and treatment potential for these cells.

#### *CD133 (prominin)*

Tirino *et al* (28) showed that CD133, a membrane glycoprotein, may be a marker of CSCs in osteosarcoma. CD133<sup>+</sup> cells were identified in three osteosarcoma cell lines (Saos2, MG63, U2OS). The CD133<sup>+</sup> cells were further characterised to be more proliferative, overexpress OCT3/4 and ABCG2, have a small side population fraction and formed spheres in serum-free

conditions while CD133<sup>-</sup> cells did not. Interestingly, the authors detected intracellular CD133 staining in CD133<sup>+</sup> and CD133<sup>-</sup> cells and reported that mRNA levels of CD133 were identical between the two populations. The group was unable to grow CD133<sup>+</sup> or CD133<sup>-</sup> tumours *in vivo*. In a follow up study, CD133<sup>+</sup> cells were shown to be present in two human primary osteosarcomas and exhibiting stem-like gene expression (e.g. OCT3/4, Nanog), sphere formation and side population fractions (29). In addition, cells isolated from CD133<sup>+</sup> derived spheres were shown to form large tumours *in vivo* compared to the adherent cells. Interestingly, in both studies it was shown that CD133<sup>+</sup> cells could give rise to CD133<sup>-</sup> cells in culture suggesting a phenotypic switch.

The expression of CD133 on FFPE samples of human osteosarcoma was shown by He *et al* (30) who detected the marker on 46 out of 70 analysed samples and positively correlated CD133 expression with lung metastases and decreased overall survival. In addition, characterisation of MG63 cells showed that CD133<sup>+</sup> subsets were more migratory, invasive and overexpressed Oct4, Nanog and CXCR4. CD133<sup>+</sup> cells in patient samples of osteosarcoma and a CD133<sup>+</sup> sub-population in Saos2 cells were also reported by Li *et al* (31). A comprehensive assessment of CD133 expression and associated CSC phenotypes on cell lines (Saos2, U2OS, MG63, HOS, MNNG/HOS, 143B) and primary tumours was followed by in depth analysis of miRNA expression profiling which identified miR-133a in connection with CD133 expression (32). The micro RNA was further shown to regulate tumorigenic potential since silencing in combination with chemotherapeutic treatment significantly reduced the aggressive tumour type and lung metastases *in vivo*. Interestingly, CD133 expression could be induced by chemotherapy treatment and was associated with enhanced miR-133a expression suggesting a CSC induction through therapeutic challenge. Overall, CD133 appears as potential therapeutic target in osteosarcoma and pharmacologic induction of a

switch from the CD133<sup>+</sup> to CD133<sup>-</sup> phenotype through siRNA could be a new therapeutic approach.

#### *CD117 (c-kit), Stro-1*

A study assessing the feasibility of using MSC surface markers to enrich for CSCs in osteosarcoma was done by Adhikari *et al* (33), who convincingly showed that CD117<sup>+</sup>/Stro-1<sup>+</sup> double-positive cells were present in mouse and human osteosarcoma cell lines as well as primary cultures. Intriguingly, the double-positive fraction showed higher sphere formation ability, increased resistance to doxorubicin treatment and overexpressed CXCR4 and ABCG2. Furthermore, double-positive cells more readily formed tumours at a lower cell number and it was shown that this CSC fraction had increased metastatic potential compared to double negative cells. This study was one of the first to comprehensively assess the molecular constitution of the identified CSCs and to furthermore show functional CSC characteristics in a number of experiments.

#### *CD271*

CD271 is a neural crest low-affinity nerve growth factor receptor and a marker of bone marrow mesenchymal stem cells. A study investigating the stem like phenotype in CD271<sup>+</sup> cells was performed by Tian *et al* (34). CD271<sup>+</sup> cells were found on FFPE tissue of human osteosarcoma samples and the cell lines MNNG/HOS, U2OS and Saos2 also contained CD271<sup>+</sup> subpopulations. The authors went on to show that CD271<sup>+</sup> cells had upregulated stem cell gene expression, resistance to chemotherapy and were more readily detected in spheres. When CD271<sup>+</sup> and CD271<sup>-</sup> cells were separated the CD271<sup>+</sup> fraction showed higher

tumorigenic potential in the sphere formation assay and when injected into immunocompromised mice.

### *Sphere formation assays*

Tissue stem cells have been identified through the ability of cells to form spheres and this method has also been used to assess CSC presence. Sarcospheres (spheres growing from sarcoma cells) have been grown under similar experimental set ups to those published for neural stem cells including non-adherent, serum-free conditions and the supplementation of media with growth factors (N2, epidermal growth factor etc.).

The first to describe osteosarcoma stem cells using sphere formation was Gibbs *et al* in 2005 (35). This was followed by several other groups, which further showed that sphere forming cells were tumorigenic in immunodeficient mice and that these cells were more drug resistant suggesting a CSC phenotype (36). A detailed study on the sphere forming fraction of MNNG/HOS cells was done by Martins-Neves *et al* (37) who showed that cells isolated from spheres had mesenchymal stem cell properties including upregulated gene expression of stemness genes Oct3/4, Nanog, and ABC transporters. They went on to show that sphere cells were more resistant to chemotherapy and radiation and that these cells exhibited higher cancer-initiating properties *in vivo* when compared to parental cells. It is noteworthy that the main CSC selection method was sphere formation suggesting that the experimental conditions of this assay induced CSC-like characteristics. Indeed, the same group later showed that the selection or enrichment method (i.e., sphere forming ability, side population analysis or ALDH activity) applied to each cell line of a larger panel was pre-selecting CSCs with specific and dissimilar characteristics in single cell lines (38). Importantly,

these data suggest that CSCs with specific molecular and functional characteristics are enriched depending on the methods and thus heterogeneous CSC sub-populations may exist side by side in one and the same cancer cell line. To our knowledge this study is one of very few applying several initial CSC enrichment methods on the same samples thus suggesting that heterogeneity may be present within the osteosarcoma CSC population.

The potential plasticity of the CSC phenotype in osteosarcoma was shown by Zhang *et al* (39). The authors presented that MNNG/HOS, Saos2 and MG63 cells readily formed spheres and that treatment with TGF $\beta$ 1 or application of hypoxic conditions (both abundant in the bone microenvironment) significantly increased sphere formation suggesting an induction of CSCs through environmental factors. Sphere cells had increased stem like factor and ABC transporter expression levels, increased resistance to cisplatin and adriamycin and *in vivo* tumour formation. The role of TGF in general tumour progression was widely studied and its role in osteosarcoma suspected (40). Indeed, the relevance of TGF $\beta$ 1 to propagate a stem like phenotype in osteosarcoma was shown when inhibition of the TGF $\beta$ 1-receptor resulted in reduced sphere formation. *In vivo* experiments using CSCs from spheres, CSCs from TGF $\beta$ 1-induced spheres and parental cells further confirmed the enrichment of aggressive CSCs in the TGF $\beta$ 1-induced sphere population since this group was capable of forming the most tumours. The authors concluded that CSCs may develop de novo from differentiated cancer cells and that they can revert back into a more differentiated state underlining a potential of plasticity. In addition, the study elegantly highlights the importance of the microenvironment (or experimental conditions) for CSCs.

MicroRNAs (miRNA) regulate gene expression on a post-transcriptional level and have been proposed to be involved in cancer progression and initiation. The micro RNA miR-

26a was shown to be significantly lower in sarcospheres or the ALDH positive fraction of several osteosarcoma cell lines compared to the parental lines (41). Doxorubicin treatment also reduced miR-26a levels suggesting an increase in stem like cells after treatment and a correlation between low miR-26a levels and CSCs. This was confirmed since over-expression of miR-26a significantly reduced gene expression of stemness markers, resulted in fewer and smaller spheres, formed fewer tumours and increased the sensitivity to chemotherapeutic challenge compared to control. As a mechanism the group suggested that miR-26a reduces osteosarcoma malignancy via Jagged1 (notch pathway) suppression. Importantly, analysis of miR-26a levels in patient samples linked high levels to a better prognosis. Finally, a link between osteosarcoma CSCs and telomerase activity was reported by Yu *et al* after detection of cells with high telomerase activity under sphere formation conditions (42).

#### *Induction of cancer stem cell phenotype through chemotherapeutic treatment*

The presence of a therapy-resistant, tumorigenic sub-population of cancer cells in a tumour is visible in patients with refractory disease and significantly highlights the necessity to further understand the nature of these cells. This chemoresistant characteristic has been exploited in a few studies investigating whether chemotherapy treated or treatment-resistant cells could contain CSCs (43-46). Indeed, it was shown that methotrexate pre-treated or resistant cells not only expressed CD117<sup>+</sup>/Stro-1<sup>+</sup> and had a side population but that these cells also formed more spheres *in vitro* and were more tumorigenic when injected subcutaneously into immunodeficient mice (44). The finding that cells with CSC characteristics could be enriched by treatment via activated Notch signalling pathways was shown in a recent study using cisplatin-resistant 143B and U2Os cells (46). Cisplatin-resistant

cells were enriched for CD117<sup>+</sup>/Stro-1<sup>+</sup> double-positive cells, formed more spheres and were more tumorigenic *in vivo*. Importantly, the group also assessed relapsed tumours after cisplatin treatment *in vivo* and reported an increase in CSCs with elevated Oct4, Sox2, CD117, Stro-1 levels and sphere formation capability.

The exploitation of chemoresistant cancer cell traits was also used by Martins-Neves *et al* (43) who found that stem-like cells could be induced with chemotherapy treatment in a number of fibroblastic and osteoblastic osteosarcoma cell lines. The identified treatment-induced cells had increased ALDH<sup>high</sup> populations, upregulated ABC transporters and showed overexpression of stemness genes as well as Wnt/beta-catenin signalling pathways. The stem like features could be reduced when the Wnt/beta-catenin pathway was inhibited *in vitro* and it was shown that a combination of chemotherapy and Wnt-inhibitor was the most efficacious anti-tumour treatment *in vivo*. The findings of the induction of a stem-like phenotype through chemotherapy were strengthened with the correlation of 'poor response' to chemotherapy and stem-like gene expression in osteosarcoma patients. The selection of an aggressive CSC phenotype after cisplatin treatment could be suggested by the work of Tsuchida *et al* (45). Side population cells of the HOS cell line treated or not treated with cisplatin were isolated and while cisplatin-induced side population cells formed tumours *in vivo* the side population fraction isolated from untreated cells did not. Furthermore, cisplatin-induced activation of VEGF/Flt1 signalling was reported to accumulate the highly tumorigenic CSC-type cells.

Collectively the reports using chemotherapeutics show that a CSC phenotype can be induced through therapeutic challenge. It remains to be established whether different chemotherapeutic challenges will give rise to different CSC sub-populations.

## Conclusion

The debate about a cancer stem cell definition is still ongoing and importantly it is not clear whether the stem cell phenotype of a cancer cell is intrinsic or plastic. Tumour cells can switch in and out of a stem cell phenotype further increasing the complexity of the cancer stem cell hypothesis and suggesting that environmental pressure (experimental or in patients) may be a trigger for heterogeneity and plasticity. For example increased environmental pressure through chemotherapy treatment has the potential to induce a switch from a differentiated towards a stem-like phenotype in osteosarcoma (43-46). This potential plasticity and the many different experimental enrichment methods may help to understand the variations of reported CSC markers between studies. Importantly it appears that the enriched CSC phenotype may depend on the applied isolation method(s), however, more studies are required to verify this. Moreover, it is currently unclear whether CSCs inherently exhibit metastasis-initiating properties.

The high level of heterogeneity found in osteosarcoma, including the effect of the tumour microenvironment may be more comprehensively assessed in PDX (patient derived xenograft) models and evidence exists that cells with CSC phenotype are present in patient derived osteosarcoma samples (24, 46). The use of patient derived material could potentially not only reflect the high heterogeneity of this rare cancer but would also reflect the influence of the human microenvironment in more detail compared to studies on cell lines. Despite these potential advantages the approach may be limited by the low availability of primary chemo-naïve tumours. The potential expansion of CSCs through the growth of PDX material *in vivo* could possibly help overcome this limitation and requires further in depth



investigation in both model development and CSC research in these models. Moreover technical refinements and research on novel techniques may allow the identification and isolation of pure subpopulations of CSCs from osteosarcoma. The major goal and biological interest of CSC research is the identification of specific treatment targets to effectively deplete CSCs. Several studies have linked CSCs directly to clinical events (24, 30, 41, 43) in osteosarcoma and treatment studies have reported inhibition of osteosarcoma CSCs or the CSC phenotype (reviewed in 7) suggesting that these elusive cells can indeed be targeted.

### **Acknowledgements**

This work was supported by the Bone Cancer Research Trust (UK, research project number 144681). We thank Prof. Gouin (Inserm, UMR957, Nantes University Hospital, France) for osteosarcoma images.

### **Conflict of interest**

The authors declare no conflict of interest.

## References

1. Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. *Nature communications*. 2015;6:8940.
2. Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. *Genome Biol*. 2014;15(8):453.
3. Kim KT, Lee HW, Lee HO, Kim SC, Seo YJ, Chung W, et al. Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. *Genome Biol*. 2015;16:127.
4. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. *Nature*. 2011;472(7341):90-4.
5. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science*. 2014;344(6190):1396-401.
6. Ryu D, Joung JG, Kim NK, Kim KT, Park WY. Deciphering intratumor heterogeneity using cancer genome analysis. *Hum Genet*. 2016;135(6):635-42.
7. Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, et al. Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. *Stem cells international*. 2016;2016:3631764.
8. Tao J, Jiang MM, Jiang L, Salvo JS, Zeng HC, Dawson B, et al. Notch activation as a driver of osteogenic sarcoma. *Cancer cell*. 2014;26(3):390-401.
9. Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. *Oncogene*. 2014;33(40):4857-66.
10. Basu-Roy U, Basilico C, Mansukhani A. Perspectives on cancer stem cells in osteosarcoma. *Cancer letters*. 2013;338(1):158-67.
11. Halldorsson A, Brooks S, Montgomery S, Graham S. Lung metastasis 21 years after initial diagnosis of osteosarcoma: a case report. *J Med Case Rep*. 2009;3:9298.
12. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. *Cancer research*. 2006;66(19):9339-44.
13. Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, et al. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. *Oncogene*. 2012;31(18):2270-82.
14. Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, et al. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. *Nature communications*. 2015;6:6411.
15. He S, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. *Annu Rev Cell Dev Biol*. 2009;25:377-406.
16. Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, et al. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. *Oncotarget*. 2016.
17. Heymann DR, F . Bone sarcomas: pathogenesis and new therapeutic approaches. *IBMS BoneKEy*. 2011;8:402-14.
18. Tirino V, Desiderio V, Paino F, Papaccio G, De Rosa M. Methods for cancer stem cell detection and isolation. *Methods Mol Biol*. 2012;879:513-29.

19. Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. *Nature reviews Cancer*. 2012;12(11):767-75.
20. Fukuda K, Saikawa Y, Ohashi M, Kumagai K, Kitajima M, Okano H, et al. Tumor initiating potential of side population cells in human gastric cancer. *International journal of oncology*. 2009;34(5):1201-7.
21. Moserle L, Indraccolo S, Ghisi M, Frasson C, Fortunato E, Canevari S, et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. *Cancer research*. 2008;68(14):5658-68.
22. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2013;27(1):13-24.
23. Murase M, Kano M, Tsukahara T, Takahashi A, Torigoe T, Kawaguchi S, et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. *British journal of cancer*. 2009;101(8):1425-32.
24. Yang M, Yan M, Zhang R, Li J, Luo Z. Side population cells isolated from human osteosarcoma are enriched with tumor-initiating cells. *Cancer Sci*. 2011;102(10):1774-81.
25. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. *Oncology reports*. 2010;24(2):501-5.
26. Greco N, Schott T, Mu X, Rothenberg A, Voigt C, McGough RL, 3rd, et al. ALDH Activity Correlates with Metastatic Potential in Primary Sarcomas of Bone. *Journal of cancer therapy*. 2014;5(4):331-8.
27. Wang L, Park P, Zhang H, La Marca F, Lin CY. Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. *International journal of cancer*. 2011;128(2):294-303.
28. Tirino V, Desiderio V, d'Aquino R, De Francesco F, Pirozzi G, Graziano A, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. *PloS one*. 2008;3(10):e3469.
29. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, et al. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2011;25(6):2022-30.
30. He A, Qi W, Huang Y, Feng T, Chen J, Sun Y, et al. CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study. *Experimental and therapeutic medicine*. 2012;4(3):435-41.
31. Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM, et al. CD133 expression in osteosarcoma and derivation of CD133(+) cells. *Molecular medicine reports*. 2013;7(2):577-84.
32. Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, et al. Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. *Stem cells*. 2014;32(4):959-73.
33. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. *Cancer research*. 2010;70(11):4602-12.
34. Tian J, Li X, Si M, Liu T, Li J. CD271+ osteosarcoma cells display stem-like properties. *PloS one*. 2014;9(6):e98549.

35. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. *Neoplasia*. 2005;7(11):967-76.
36. Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. *International journal of oncology*. 2009;34(5):1381-6.
37. Martins-Neves SR, Lopes AO, do Carmo A, Paiva AA, Simoes PC, Abrunhosa AJ, et al. Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. *BMC cancer*. 2012;12:139.
38. Martins-Neves SR, Corver WE, Paiva-Oliveira DI, van den Akker BE, Briaire-de-Bruijn IH, Bovee JV, et al. Osteosarcoma Stem Cells Have Active Wnt/beta-catenin and Overexpress SOX2 and KLF4. *Journal of cellular physiology*. 2016;231(4):876-86.
39. Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, et al. Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. *Stem cells*. 2013;31(3):433-46.
40. Lamora A, Talbot J, Mullard M, Brounais-Le Royer B, Redini F, Verrecchia F. TGF- $\beta$  Signaling in bone remodeling and osteosarcoma progression. *J Clin Med*. 2016;5(11).
41. Lu J, Song G, Tang Q, Yin J, Zou C, Zhao Z, et al. MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1. *Oncogene*. 2016.
42. Yu L, Liu S, Zhang C, Zhang B, Simoes BM, Eyre R, et al. Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. *Oncotarget*. 2013;4(12):2326-38.
43. Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovee JV, et al. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling. *Cancer letters*. 2016;370(2):286-95.
44. Tang QL, Liang Y, Xie XB, Yin JQ, Zou CY, Zhao ZQ, et al. Enrichment of osteosarcoma stem cells by chemotherapy. *Chinese journal of cancer*. 2011;30(6):426-32.
45. Tsuchida R, Das B, Yeger H, Koren G, Shibuya M, Thorner PS, et al. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. *Oncogene*. 2008;27(28):3923-34.
46. Yu L, Fan Z, Fang S, Yang J, Gao T, Simoes BM, et al. Cisplatin selects for stem-like cells in osteosarcoma by activating notch signaling. *Oncotarget*. 2016.
47. Penfornis P, Cai DZ, Harris MR, Walker R, Licini D, Fernandes JD, et al. High CD49f expression is associated with osteosarcoma tumor progression: a study using patient-derived primary cell cultures. *Cancer medicine*. 2014;3(4):796-811.

**Figure 1: Representative imaging of osteoblastic osteosarcoma. (A)** Macroscopic view of a resected osteosarcoma infiltrating surrounding soft tissue. Conventional X-ray **(B)** and **(C)** Magnetic Resonance Imaging (MRI) of osteosarcoma. **(D)** Computed tomography of an osteosarcoma in a 15-year old patient (adapted from “Bone Cancer” 1<sup>st</sup> Edition, Ed. Heymann D., Academic Press, 2009). Tumour tissue is composed by mineralized component detectable to X-Ray (\*) and is strongly associated with the vasculature (arrows). **(E)** Typical histological view showing osteoid extracellular matrix produced by osteosarcoma cells (\*), tumour tissue is vascularized (arrow head). **(F)** Sarcosphere generated from the human MNNG-HOS osteosarcoma cell line under non-adherent serum-free conditions.

**Table 1:** Studies investigating CSCs in osteosarcoma

Initial CSC identification/enrichment method	Osteosarcoma cell lines/patient samples	Characterisation of enriched CSC phenotype	Reference
Side population	OS2000, KIKU, NY, Huo9, HOS, U2OS and Saos2	Sphere formation, stem like gene expression, <i>in vivo</i> tumorigenicity	(23)
	Human primary, U2OS	Stem like genes, sphere formation, drug resistance, <i>in vivo</i> tumorigenicity	(24)
ALDH	MG63	Stem like gene expression, drug resistance, sphere formation	(25)
	OS99-1 Hu09, Saos-2, MG63	Stem like gene expression, <i>in vivo</i> tumorigenicity	(27)
CD133	Saos2, MG63, U2OS	Stem like gene expression, side population, sphere formation	(28)
	Human primary	Stem like genes, side population, sphere formation, <i>in vivo</i> tumorigenicity	(29)
	Human primary (FFPE), MG63	Stem like gene expression	(30)
	Human primary (FFPE), Saos2	Stem like gene expression	(31)
	Human primary, Saos2, U2OS, MG63, HOS, MNNG/HOS, 143B	Sphere formation, drug resistance, <i>in vivo</i> tumorigenicity, stem like gene expression	(32)
CD117/Stro-1	K7M2, KHOS/NP, MNNG/HOS, 318-1, P932, BCOS	Sphere formation, drug resistance, stem like gene expression, <i>in vivo</i> tumorigenicity and metastatic potential	(33)
CD271	Human primary (FFPE), MNNG/HOS, U2OS, Saos2	Stem like gene expression, sphere formation, drug resistance, <i>in vivo</i> tumorigenicity	(34)
Sphere formation	Human primary, MG63	Stem like gene expression	(35)
	MG63	Drug resistance, <i>in vivo</i> tumorigenicity	(36)
	MNNG/HOS	Stem like gene expression, drug resistance, <i>in vivo</i> tumorigenicity	(37)
Sphere formation, ALDH, side population	HOS, MG-63, MHM, MNNG-HOS, SJS-1, L2531, L3312, OHS, U2OS	Stem like gene expression, <i>in vivo</i> tumorigenicity	(38)
Sphere formation	MNNG/HOS, Saos2, MG63 + TGFβ/hypoxia	<i>In vivo</i> tumorigenicity, drug resistance, stem like gene expression	(39)
Sphere formation, chemotherapeutic treatment, ALDH	Human primary, U2OS, MG63, Saos-2 and 143B, link to miR-26a	Stem like gene expression, <i>in vivo</i> tumorigenicity, drug resistance	(41)
Chemotherapeutic treatment	U2Os	CD117 <sup>+</sup> /Stro-1, side population, sphere formation, <i>in vivo</i> tumorigenicity	(44)
	Cisplatin-resistant 143B and U2Os	CD117 <sup>+</sup> /Stro-1 <sup>+</sup> , sphere formation, <i>in vivo</i> tumorigenicity, stem like gene expression	(42)
	HOS, MG-63, MHM, MNNG-HOS, OHS, U2OS	ALDH high, stem like gene expression	(43)
	HOS	Side population, <i>in vivo</i> tumorigenicity, stem like gene expression	(45)

Figure 1

